Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9495051 | 0.85 | HPGD (0.44) | KMT2AHPGDLMNACA2CA1 | |
| SCHEMBL321565 | 0.80 | KEAP1 (0.47) | KMT2AHPGDLMNACA12CA2 | |
| SCHEMBL11663915 | 0.79 | HPGD (0.40) | KMT2AHPGDLMNACA12CA2 | |
| SCHEMBL1017480 | 0.79 | HPGD (0.72) | KMT2AHPGDLMNACA12CA2 | |
| SCHEMBL3634388 | 0.77 | KMT2A (0.59) | KMT2ACA12CA2CA9CA1 | |
| SCHEMBL9490752 | 0.77 | HPGD (0.70) | KMT2AHPGDLMNACA12CA2 | |
| SCHEMBL28791142 | 0.76 | HPGD (0.50) | KMT2AHPGDLMNACA12CA2 | |
| SCHEMBL1679405 | 0.75 | KIF11 (0.41) | KMT2AHPGDLMNACA12CA2 | |
| SCHEMBL9489980 | 0.75 | HPGD (0.57) | KMT2AHPGDLMNACA12CA2 | |
| SCHEMBL1018533 | 0.74 | TSHR (0.54) | KMT2ACA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9067929-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8586600-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8242271-B2 | Heterocyclic compounds and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2152079-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008151183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | KMT2A 3534/4885HPGD 116/4885LMNA 1530/4885 |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | KMT2A 3534/4885HPGD 116/4885LMNA 1530/4885 |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | KMT2A 3534/4885HPGD 116/4885LMNA 1530/4885 |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | KMT2A 3534/4885HPGD 116/4885LMNA 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.